Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.
Several other equities research analysts have also recently commented on ARWR. Jefferies Group reaffirmed a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Finally, Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.70.
Shares of Arrowhead Pharmaceuticals (ARWR) traded up $0.03 during trading hours on Thursday, hitting $3.57. The stock had a trading volume of 1,181,040 shares, compared to its average volume of 972,484. Arrowhead Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $4.54. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.